The genomic landscape of juvenile myelomonocytic leukemia-Reference-Cited by-同舟云学术

The genomic landscape of juvenile myelomonocytic leukemia

Published:2015-10-12 Issue:11 Volume:47 Page:1326-1333
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Stieglitz Elliot^ORCID,Taylor-Weiner Amaro N,Chang Tiffany Y,Gelston Laura C,Wang Yong-Dong,Mazor Tali,Esquivel Emilio,Yu Ariel^ORCID,Seepo Sara,Olsen Scott R,Rosenberg Mara,Archambeault Sophie L^ORCID,Abusin Ghada,Beckman Kyle,Brown Patrick A,Briones Michael,Carcamo Benjamin,Cooper Todd,Dahl Gary V,Emanuel Peter D,Fluchel Mark N,Goyal Rakesh K,Hayashi Robert J,Hitzler Johann,Hugge Christopher,Liu Y Lucy,Messinger Yoav H,Mahoney Donald H,Monteleone Philip,Nemecek Eneida R,Roehrs Philip A,Schore Reuven J,Stine Kimo C,Takemoto Clifford M,Toretsky Jeffrey A,Costello Joseph F,Olshen Adam B,Stewart Chip,Li Yongjin,Ma Jing,Gerbing Robert B,Alonzo Todd A,Getz Gad,Gruber Tanja A,Golub Todd R,Stegmaier Kimberly,Loh Mignon L

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.3400.pdf

Reference78 articles.

1. Chang, T.Y., Dvorak, C.C. & Loh, M.L. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood 124, 2487–2497 (2014).

2. Dvorak, C.C. & Loh, M.L. Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Front. Pediatr. 2, 25 (2014).

3. Matsuda, K. et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 109, 5477–5480 (2007).

4. Matsuda, K. et al. Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations. Blood 115, 5429–5431 (2010).

5. Bresolin, S. et al. Gene expression–based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J. Clin. Oncol. 28, 1919–1927 (2010).

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia;2024-08-02

2. Mechanistic insights into the developmental origin of pediatric hematologic disorders;Experimental Hematology;2024-08

3. Clinicopathologic characteristics of de novo NF1 -mutated acute myeloid leukemia;Leukemia & Lymphoma;2024-07-27

4. Comparative analysis of dynamic transcriptomes reveals specific COVID-19 features and pathogenesis of immunocompromised populations;mSystems;2024-06-18

5. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group;Cancer Discovery;2024-06-11